home > news

> News

> EnteroBiotix Announces Positive Topline Phase 2a Results with EBX-102-02, a Potential First-in-Class Treatment for Irritable Bowel Syndrome (IBS)

News

21/03/2025

EnteroBiotix Announces Positive Topline Phase 2a Results with EBX-102-02, a Potential First-in-Class Treatment for Irritable Bowel Syndrome (IBS)

Read the full article below.

https://www.enterobiotix.com/news/enterobiotix-announces-positive-topline-phase-2a-results-with-ebx-102-02

Our news

News

21/07/2025
EMIH response to the European Commission call for evidence on the EU Biotech Act
> READ

Events

19/01/2023
Microbiota & Health Day 2023
> READ

News

25/09/2024
European Microbiome Innovation for Health and Microbiome Therapeutics Innovation Group join forces with Microbiome Times on important deal-making event, taking place Brussels 2025
> READ

> See all news